28
Oct
2025

Yuxi Walvax Biotechnology Co., Ltd.

Exhibitor at CPHI Frankfurt 2025 stand 4.1B48, Finished Dosage Formulations
About Us

Founded in 2001, Walvax Biotechnology Co. Ltd. is mainly engaged in research and development, manufacturing and distribution of safe and efficacious human vaccines. Walvax is a leading public listed company in China and has successfully developed 9 licensed vaccines (13 presentations). Among the 9 licensed products, Walvax has world’s 2nd approved PCV-13, 4th approved mRNA Covid-19 vaccine and 5th approved HPV vaccine. 

  • CN
  • 2023
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 4.1B48, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025